Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
Phase 2
Recruiting
Conditions
Post-Transplant Lymphoproliferative Disorder
Refractory Mantle Cell Lymphoma
Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder
Recurrent Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Neoplastic Post-Transplant Lymphoproliferative Disorder
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Expand All (11)
Interventions
Biological: Loncastuximab Tesirine
Subscribe
First Posted Date
2022-07-12
Last Posted Date
2024-10-17
Lead Sponsor
University of Washington
Target Recruit Count
40
Registration Number
NCT05453396
Locations
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy